

ผลของสารเฮสเพอริดินต่อความจำบกพร่องในหนูแรทที่ถูกเหนี่ยวนำด้วย

เมโธเทรกเซท

สาลิณี แนวลา¹, กรรวิ สุวรรณโคตร¹, วณันันท์ เป็นนางรอง¹, จาริยา อัมคา เวลบาท^{1,2*}

¹ภาควิชากายวิภาคศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น

²กลุ่มวิจัยและพัฒนาด้านประสาทวิทยาศาสตร์ มหาวิทยาลัยขอนแก่น

Effects of Hesperidin on Memory Impairments Induced by Methotrexate

in Adult Rats

Salinee Naewla¹, Kornrawee Suwannakot¹, Wanassanun Pannangrong¹, Jariya Umka Welbat^{1,2*}

¹Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

²Neuroscience Research and Development Group, Khon Kaen University, Khon Kaen 40002, Thailand.

หลักการและวัตถุประสงค์: เมโธเทรกเซท (methotrexate) เป็นยาเคมีบำบัดที่ใช้ในการรักษาโรคมะเร็งหลายชนิด การศึกษารายงานว่าเมโธเทรกเซท มีผลเป็นพิษต่อระบบประสาท เหนี่ยวนำให้เกิดภาวะความจำบกพร่อง เฮสเพอริดิน (hesperidin) เป็นสารธรรมชาติ มีคุณสมบัติลดการอักเสบ และต้านอนุมูลอิสระ นอกจากนี้เฮสเพอริดินยังมีฤทธิ์กระตุ้นการเรียนรู้และความจำ ดังนั้นการวิจัยนี้จึงมีวัตถุประสงค์เพื่อศึกษาผลของเฮสเพอริดิน ต่อความจำบกพร่องที่เกิดจากเมโธเทรกเซท

วิธีการศึกษา: หนูแรทเพศผู้ จำนวน 24 ตัว สายพันธุ์ Sprague Dawley อายุ 4-5 สัปดาห์ ถูกแบ่งออกเป็น 4 กลุ่ม กลุ่มละ 6 ตัว กลุ่มควบคุม (vehicle group) ได้รับน้ำเกลือและโพรพิลีน ไกลคอล กลุ่มเฮสเพอริดิน (hesperidin group) ได้รับเฮสเพอริดิน กลุ่มเมโธเทรกเซท (methotrexate group) ได้รับเมโธเทรกเซท และกลุ่มเมโธเทรกเซทร่วมกับเฮสเพอริดิน (methotrexate+hesperidin group) ได้รับเมโธเทรกเซทร่วมกับเฮสเพอริดิน โดยเมโธเทรกเซทถูกฉีดให้กับหนูกลุ่มเมโธเทรกเซท และกลุ่มเมโธเทรกเซทร่วมกับเฮสเพอริดิน ในปริมาณ 75 มิลลิกรัม/กิโลกรัม ทางหลอดเลือดดำในวันที่ 8 และ 15 ของการทดลอง และได้รับเฮสเพอริดินทางปาก เป็นเวลา 21 วัน หลังจากสิ้นสุดการให้สาร 3 วัน หนูถูกทดสอบความจำโดยการทดสอบ novel object location และ novel object recognition

ผลการศึกษา: ผลการศึกษา พบว่าการทดสอบ novel object location และ novel object recognition ค่าระยะเวลาการ

Background and objectives: Methotrexate is a chemotherapy drug used to treat many different cancers. Several studies have reported that methotrexate has neurotoxic effects, leading to memory impairments. Hesperidin is a natural compound which exhibits anti-inflammatory and antioxidant properties. Furthermore, hesperidin enhances learning and memory. Therefore, the aim of this study was to investigate the effect of hesperidin on memory impairment caused by methotrexate.

Methods: Twenty-four male Sprague Dawley rats (age: 4-5 weeks) were divided into 4 groups (6 animals/group). Vehicle group received saline and propylene glycol. Hesperidin group received hesperidin only. Finally, methotrexate group received only methotrexate and methotrexate+hesperidin group received both methotrexate and hesperidin. A single dose of methotrexate (75 mg/kg) was administered by intravenous injection on day 8 and 15. Hesperidin (100 mg/kg) was administered per oral for 21 days. Three days after the end of drug administration, memory was tested using the novel object location and novel object recognition.

Results: The results showed that total exploration

*Corresponding author : Jariya Umka Welbat, Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen Thailand, 40002. Email: jariya@kku.ac.th

สำรวจวัตถุทั้งหมดในแต่ละกลุ่มไม่แตกต่างกันอย่างมีนัยสำคัญทางสถิติ ($p > 0.05$) การทดสอบ novel object location พบว่าหนูในกลุ่มควบคุม กลุ่มเฮสเพอริดิน และกลุ่มเมโธเทรกเซทร่วมกับเฮสเพอริดิน สามารถแยกความแตกต่างระหว่างวัตถุในตำแหน่งใหม่และตำแหน่งเก่าได้อย่างมีนัยสำคัญทางสถิติ ($p < 0.05$) และเมื่อทำการทดสอบ novel object recognition พบว่าหนูในกลุ่มควบคุม กลุ่มเฮสเพอริดิน และกลุ่มเมโธเทรกเซทร่วมกับเฮสเพอริดิน สามารถแยกความแตกต่างระหว่างวัตถุใหม่และวัตถุเก่าได้ ในขณะที่กลุ่มเมโธเทรกเซทไม่สามารแยกความแตกต่างระหว่างวัตถุใหม่และวัตถุเก่าได้ อย่างมีนัยสำคัญทางสถิติ ($p < 0.05$)

สรุป: การศึกษาในครั้งนี้ชี้ให้เห็นว่าเฮสเพอริดิน สามารถป้องกันและฟื้นฟูความจำบกพร่องที่ถูกเหนี่ยวนำจากเมโธเทรกเซทในหนูแรทโตเต็มวัย

คำสำคัญ: เฮสเพอริดิน, เมโธเทรกเซท, ความจำบกพร่อง

time was not significantly different among groups in both novel object location and novel object recognition tests ($p > 0.05$). In novel object location test, rats in vehicle, hesperidin and methotrexate+hesperidin groups could significantly discriminate between the objects placed in the novel and familiar locations ($p < 0.05$). Similar, in the novel object recognition test, rats in vehicle, hesperidin and methotrexate+hesperidin groups could significantly discriminate between the novel and familiar objects, whereas rats in methotrexate group did not discriminate between the novel and familiar objects ($p < 0.05$).

Conclusion: The results of this experiment indicated that hesperidin is able to prevent and improve the memory impairments induced by methotrexate in adult rats.

Keyword: Hesperidin, Methotrexate, Memory impairment

ศรีนครินทร์เวชสาร 2562; 34(1): 26-35. • Srinagarind Med J 2019; 34(1): 26-35.

Introduction

Chemotherapy is the most importance for cancer treatment and increases survival rate of patients¹⁻³. However, the treatment induces memory impairment, which decreases concentration, speed of information processing and memory⁴. Methotrexate is the first line therapy as of disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis⁵. Furthermore, it is usually used in cancer treatments. Methotrexate inhibits the activity of dihydrofolate reductase (DHFR), which converts an inactive form of folic acid-dihydrofolate (DHF) into the active form-tetrahydrofolate (THF). Methotrexate is a powerful disruption of DNA synthesis⁶. However, neurotoxicity of methotrexate can be as a result of reactive oxygen species (ROS). Methotrexate causes an increase of apoptosis and significant reduction of hippocampal cell proliferation that lead to memory impairment⁶⁻⁸. Several reports have shown that side effects of methotrexate cause alterations of learning and memory⁸⁻¹². Therefore, compounds with antioxidant properties may protect

memory impairments from harmful effects of methotrexate.

Natural compounds such as flavonoids are very effective in neurodegenerative disease. Hesperidin, a flavonoid, is a part of natural flavanone group¹³. It can be found in citrus species, such as oranges, lemons and vegetables. Hesperidin exhibits various bioactivities, including anti-inflammatory, antioxidant defense mechanism and neuroprotective effects^{13, 14}. It modulates neuronal signaling pathways, which involves in synaptic plasticity^{14, 15}. In addition, hesperidin can enhance learning and memory¹⁶ and it is potential in the treatment of neurodegenerative diseases¹⁴. Several evidences have shown that hesperidin (100 mg/kg/day) enhances cognitive and antioxidative stress¹⁷.

Therefore, the aim of this study was to investigate the effect of hesperidin on memory impairments induced by methotrexate. The memory was tested using novel object location (NOL) and novel object recognition (NOR) tests.

Material and Methods

Animals and Experimental Procedures

Twenty-four male Sprague Dawley rats were 4-5 weeks old and 180-220 grams of body weight. The rats were provided from the National Laboratory Animal Center, Mahidol University, Salaya, Nakornpathom. The rats were adjusted to experimental conditions for a week period before the experiments. The rats were housed in standard laboratory conditions (25-28 °C temperature, 12 h light/12 h darkness). They were fed with food and water was supplied ad libitum. This study was approved by Animal Ethics Committee of Khon Kaen University, Khon Kaen, Thailand (ACUC-KKU-51/60).

Drug and treatment protocols

Methotrexate (pharmachemie BV, harsblem, Netherland) (75 mg/kg) was dissolved in 0.9% saline solution (Ajax Finechem Pty Ltd., Australia) for intravenous (i.v.) injection to the tail vein under anesthesia on day 8 and day 15. After methotrexate injections, leucovorin was administered to the rats by intraperitoneal (i.p.) injections at 18 hours (6 mg/kg), 26, 42 and 50 hours (3 mg/kg). The administration was similar to the application in patients in clinic. Leucovorin is clinically used to reduce cytotoxicity of methotrexate¹⁸. Hesperidin (ChemFaces Biochemical Co., Ltd., Wuhan, China) was dissolved

in propylene glycol (Faces Biochemical Co., Ltd., China). Hesperidin was used to feed per oral (PO.) at a dose of 100 mg/kg/day at 10.00 a.m. for 21 days. Rats were randomly divided into 4 groups as follows (Fig 1):

Vehicle group: rats received saline solution (i.v.) and propylene glycol (PO.)

Hesperidin group: rats received 100 mg/kg of Hsd (PO.)

Methotrexate group: rats received 75 mg/kg of methotrexate (i.v.)

Methotrexate+hesperidin group: rats received 75 mg/kg methotrexate (i.v.) and 100 mg/kg of hesperidin (PO.)

Behavioral testing

Novel object location (NOL) and novel object recognition (NOR) tests were performed in an open field black acrylic arena (50 cm × 50 cm × 50 cm). The arena was set up under an overhead digital camera connected to a computer tracking system (EthoVision®, XT Version 12, Noldus, Wageningen, Netherlands). The arena and objects were cleaned with 20% ethanol to eliminate any olfactory cues between trials and each experiment. The tests were adapted from Dix and Aggleton¹⁹. One day before NOL and NOR testing, the animals were habituated to explore environment of arena without objects for




Figure 1 Experimental protocol: timeline of drug treatment and behavioral tests.

30 minutes and they were moved immediately to their home cages. After habituation, the rats were tested using NOL and NOR tests.

NOL test

Three days after the end of drug administration, NOL test was used to investigate spatial working memory. NOL test consisted of familiarization and choice trials. In the familiarization trial, rats were moved into the center of the arena and explored two similar objects placed in different locations (location A and B) for 3 minutes. The rats were moved from the area to their cages for 15 minutes. In the choice trial, the rats were returned to the arena to explore two objects for 3 minutes, one object was placed in the same location (familiar location), while the other object was moved to a new location (novel location).

NOR test

During the familiarization trial (1 day after habituation), the rat was placed into the center of the arena to explore two similar objects placed in different locations (object 1 and 2) for 3 minutes. Then, rat was returned to their home cages for 15 minutes. During the choice trial, one of the familiar objects and a novel object were put back to the same locations. The rats were returned to the arena and explored the objects for 3 minutes.

The object exploration in NOL and NOR tests were defined as the time that the rats spend exploring the objects by sniffing or touching within 2 cm.^{19,20} The exploration time was recorded and used to calculate discrimination index (DI). DI is defined as the time difference between the novel and familiar locations or objects in the choice trail²¹⁻²⁴.

Statistical analysis

The data were expressed as mean + standard error of mean (SEM) using GraphPad Prism 6.0 software (GraphPad software Inc., San Diego, CA, USA). Body weight was analyzed using two-way repeated measure analysis of variance (ANOVA). One-way ANOVA was used for comparisons among group of

weight gain, total exploration time and DI. When ANOVA was significantly different, Bonferonni post hoc test was performed. One sample t-test was performed on DI whether the score differed from 0. A probability level of $p < 0.05$ was accepted as statistical significance.

Results

1. Effect of hesperidin and methotrexate on body weight

Rat body weight was measured daily during the experiment as shown in Fig 2. Body weight of rats in methotrexate and methotrexate+hesperidin groups significantly was less than vehicle group ($p < 0.001$, two-way repeated measure ANOVA), but not hesperidin group. After methotrexate injection, in methotrexate group, the body weight significantly reduced when compared with vehicle group on day 9 ($p < 0.05$, two-way repeated measure ANOVA) and day 18 until day 21 ($p < 0.001$, two-way repeated measure ANOVA). After day 9, rats in methotrexate group regained body weight. In addition, differences of body weight were significantly found between methotrexate+hesperidin and vehicle groups on day 18 to day 21 ($p < 0.001$, two-way repeated measure ANOVA).

2. The improvement of hesperidin on memory impairment induced by methotrexate

2.1 NOL test

- NOL test before drugs administration

To assess memory function, a NOL test was carried out before three day of drugs administration. There was a no significant difference in the total exploration ($p > 0.05$, one-way ANOVA, Fig 3A) and DI ($p > 0.05$, one-way ANOVA, Fig 3B) among the four groups. Additionally, DI of rats in all groups had higher than 0 ($p < 0.05$, one sample t-test, Fig 3B). The results indicate that rats in all groups could discriminate between two identical objects in different locations.

- NOL test three days after the end of the drug administration




Figure 2 Body weight in vehicle, hesperidin, methotrexate and methotrexate+ hesperidin groups.

Three days after drug administration, the rats were examined by NOL test to investigate the effects of hesperidin on memory impairment induced by methotrexate. Total exploration time of all groups did not show significant difference ($p > 0.05$, One-way ANOVA, Fig 4A). This result indicates that drug treatment did not affect locomotor activity. In addition, there were significant differences of DI

among groups ($p < 0.05$, one-way ANOVA, Fig 4B). Further analysis with Bonferroni Post hoc analysis reveals that DI of methotrexate group was significantly different when compared to vehicle, hesperidin and methotrexate+hesperidin groups ($p < 0.05$, Fig 4B). DI of vehicle, hesperidin and methotrexate+hesperidin groups had a significantly higher than 0, but did not find in methotrexate group




Figure 3 Total exploration times and discrimination index of the rats in the NOL test before treatment. Rats from all groups showed no significant difference in the total exploration time of the two objects ($p > 0.05$, A). Discrimination index (DI) was not significantly different among groups ($p > 0.05$, B). Data are given as mean \pm SEM.




Figure 4 Exploration times of rats in NOR test after treatment. All data are expressed as mean exploration times (mean±SEM). Total exploration time was not significantly different among groups ($p>0.05$, A). Discrimination index (DI) of vehicle, hesperidin, and methotrexate+hesperidin groups was significantly different when compared with methotrexate group. The statistical analysis was calculated using one-way ANOVA with Bonferroni's post hoc test ($*p<0.05$).




Figure 5 Total exploration time and discrimination index of the NOR before drug administration. In total exploration time, there were no significant differences among groups ($p>0.05$, A). DI of vehicle, hesperidin and methotrexate and methotrexate+hesperidin groups were not significantly different among groups ($p>0.05$, B). Data are given as mean ± SEM.

($p<0.05$, one sample t-test, Fig 4B).

2.2 NOR test

- NOR test before drugs administration

Before drugs administration, the total there was no significant difference of the exploration time

among four groups, indicating that rats in all groups had no impairment of locomotor activity to explore the objects ($p>0.05$; Fig 5A). The DI was not significantly different among groups ($p>0.05$; one-way ANOVA, 5B). Additionally, DI of rats in all groups had higher than 0 ($p<0.05$, one sample t-test, Fig 5B).




Figure 6 Total exploration times (A) and DI (B) in NOR test after drug. All data are expressed as mean exploration times (mean±SEM). The data analysis was performed using one-way ANOVA with Bonferroni’s post hoc test (* $p < 0.05$ and *** $p < 0.001$, respectively).

These indicate that all rats were able to discriminate between the novel and familiar objects.

- NOR test after the end of the drug administration

There were no significant differences in the total exploration time among groups ($p > 0.05$, one-way ANOVA, Fig 6A), which indicates no locomotor impairment. DI of rats in vehicle, hesperidin and methotrexate+hesperidin groups were significantly higher than 0, but did not find in methotrexate group ($p < 0.05$, one sample t-test, Fig 6B). The data indicates that vehicle, hesperidin and methotrexate+hesperidin groups had the ability to discriminate between familiar and novel objects. However, the rats in methotrexate group did not discriminate between two objects. DI of methotrexate group was significantly different when compared to vehicle, hesperidin and methotrexate+hesperidin groups ($p < 0.05$; $p < 0.001$ and $p < 0.05$, respectively; one-way ANOVA, Fig 6B), indicating their memory impairments.

Discussion

The present study investigated the effect of hesperidin on memory impairment after methotrexate treatment. During this study,

methotrexate and methotrexate+hesperidin groups had a significantly less body weight than control group, whereas rats treated with only hesperidin did not show. The result indicates that methotrexate treatment induced decreases of body weight. This result is related to the mechanisms of methotrexate action, which stimulates DNA and RNA synthesis and induces apoptosis in both tumor and normal tissues. Gastrointestinal tissue is most frequently observed and may lead to intestinal mucositis symptoms, such as nausea, abdominal pain, and diarrhea²⁵. It is the cause of decrease in body weight after methotrexate administration. Body weight of hesperidin group was not significantly different when compared with control group, indicating that hesperidin did not affect body weight which is consistent with a previous study²⁶.

In this study, both NOL and NOR tests were used for evaluated the memory impairment. Both tests require an intact adult neurogenesis in the SGZ of the dentate gyrus in the hippocampus. The hippocampus plays critical roles for the regulation of learning and memory²⁷. The outcome of both tests, animals with no memory impairments will spend equal time exploring two objects in the familiarization trial, while spend long time to exploring the object

in the novel location or novel object in the choice trial. Previous studies have reported that methotrexate induces memory impairments^{20, 28}. Similarly, results of the present study shows that rats treated with methotrexate (75 mg/kg) on days 8 and 15 could not discriminate between novel and familiar locations in NOL test. The NOR test, the rats treated with only methotrexate could not the discrimination a novel object from a familiar object. It indicates that animals receiving methotrexate showed memory impairments. Likewise, Yang and coworkers have confirmed that methotrexate enhances hippocampal dysfunction and cognitive impairment using novel object recognition (NOR) test²⁹. Methotrexate negatively affects neurogenesis and induces memory impairments, which are related to DNA damage and/or deficiencies in DNA repair mechanism³⁰. Additionally, methotrexate causes a reactive oxygen species (ROS) of the CNS, which may lead to neuronal toxicity, neuro-inflammation as well as neuronal cell death⁸. The present study shows that methotrexate+hesperidin groups significantly improved memory impairment as compared with methotrexate group. This was confirmed by DI in NOL and NOR test. In NOL test, rats in all groups were able to discriminate between two identical objects in novel and familiar locations. However, rats had received hesperidin for 21 days spent significantly more time exploring the object in the novel locations compared to methotrexate group. In addition, there was a significant difference in the DI between methotrexate and methotrexate+hesperidin groups. In the NOR test, the rats in all groups had no significant difference in the DI. After 21 days of drugs administered, rats receiving hesperidin was able to discriminate between novel and old object. The DI of methotrexate group was significantly reduced in comparison with hesperidine group, but rats treated with both methotrexate and hesperidin showed an increase of DI. This finding indicates that co-treatment with methotrexate and hesperidin improved memory impairments. Similarly, the administration of hesperidin (100 mg/kg) recovered memory deficits in the APPswe/PS1dE9 transgenic mouse model of

AD¹⁷. Hesperidin can enhance neuronal function and induce neurogenesis by increasing blood flow¹⁶. As mentioned, hesperidin can cross into the brain via the blood brain barrier³¹. Therefore, the hesperidin can enhance memory.

In addition to memory impairments, methotrexate reduces antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)^{32, 33}, which result in increasing cellular damage and neurogenerative diseases. Hesperidin is one of the most important antioxidants, which can protect neurogenerative diseases. Hydroxyl groups of hesperidin donates electrons to the radicals to decrease ROS³⁴. Similarly, Antunes and coworkers have found that hesperidin increases Ark/Nrf2 signaling and enhances levels of antioxidant enzymes, such as CAT, SOD, and GST in AD rat models³⁵. Also, Antunes et al.²⁰ has reported that hesperidin shows neuroprotection against neurotoxicity induced by 6-hydroxidopamine (6-OHDA) in a Parkinson's disease (PD) rat model. These evidences support our findings that hesperidin improves memory impairments in methotrexate treated-rats.

Conclusion

Hesperidin (100 mg/kg) significantly improved memory impairments caused by methotrexate. Thus, the present study shows the evidence that hesperidin may be useful as a supplement to prevent and improve memory impairments.

Acknowledgments

The authors would like to thank Neuroscience Research and Development Group, Khon Kaen University (Project number: 002/2561) and the National Research Council of Thailand (NRCT) for financially supports this work.

References

1. Wigmore P. The effect of systemic chemotherapy on neurogenesis, plasticity and memory. *Curr Top Behav Neurosci*. 2013; 15: 211-40.
2. Monje M, Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. *Behav Brain Res*. 2012; 227: 376-9.
3. Dietrich J. Chemotherapy associated central nervous system damage. *Adv Exp Med Biol*. 2010; 678: 77-85.
4. Kunin-Batson A, Kadan-Lottick N, Neglia JP. The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia. *Psychooncology*. 2014; 23: 692-9.
5. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. *Rheumatology (Oxford)*. 2002; 41: 1346-56.
6. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. *Chemotherapy*. 2003; 49: 92-104.
7. Krull KR, Brinkman TM, Li C, Armstrong GT, Ness KK, Srivastava DK, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. *J Clin Oncol*. 2013; 31: 4407-15.
8. Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, van Dam FS, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. *Behav Brain Res*. 2008; 186: 168-75.
9. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. *Br J Pharmacol*. 2003; 138: 501-11.
10. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. *Inflamm Res*. 2005; 54: 273-80.
11. Huang C, Hsu P, Hung Y, Liao Y, Liu C, Hour C, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. *Apoptosis*. 2005; 10: 895-907.
12. Hsu PC, Hour TC, Liao YF, Hung YC, Liu CC, Chang WH, et al. Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2. *Apoptosis*. 2006; 11: 389-99.
13. Garg A, Garg S, Zaneveld LJ, Singla AK. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. *Phytother Res*. 2001; 15: 655-69.
14. Tamilselvam K, Braidy N, Manivasagam T, Essa MM, Prasad NR, Karthikeyan S, et al. Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson's disease. *Oxid Med Cell Longev*. 2013; 2013: 102741.
15. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. *Free Radic Biol Med*. 2004; 37: 304-17.
16. Spencer JP. The interactions of flavonoids within neuronal signalling pathways. *Genes Nutr*. 2007; 2: 257-73.
17. Wang D, Liu L, Zhu X, Wu W, Wang Y. Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease. *Cell Mol Neurobiol*. 2014; 34: 1209-21.
18. Boarman DM, Baram J, Allegra CJ. Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells. *Biochem Pharmacol*. 1990; 40: 2651-60.
19. Dix SL, Aggleton JP. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. *Behav Brain Res*. 1999; 99: 191-200.
20. Lyons L, ElBeltagy M, Umka J, Markwick R, Startin C, Bennett G, et al. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology*. 2011; 215: 105-15.
21. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. *Cogn Process*. 2012;13(2):93-110.
22. Umka J, Mustafa S, ElBeltagy M, Thorpe A, Latif L, Bennett G, et al. Valproic acid reduces spatial working memory and cell proliferation in the hippocampus. *Neuroscience*. 2010; 166: 15-22.

23. Sirichoat A, Chaijaroonkhanarak W, Prachaney P, Pannangrong W, Leksomboon R, Chaichun A, et al. Effects of Asiatic Acid on Spatial Working Memory and Cell Proliferation in the Adult Rat Hippocampus. *Nutrients*. 2015; 7: 8413-23.
24. Chaisawang P, Sirichoat A, Chaijaroonkhanarak W, Pannangrong W, Sripanidkulchai B, Wigmore P, et al. Asiatic acid protects against cognitive deficits and reductions in cell proliferation and survival in the rat hippocampus caused by 5-fluorouracil chemotherapy. *PLoS One* . 2017; 12: e0180650.
25. Keefe DM, Brealey J, Golland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. *Gut*. 2000; 47: 632-7.
26. Yano S, Umeda D, Yamashita T, Ninomiya Y, Sumida M, Fujimura Y, et al. Dietary flavones suppresses IgE and Th2 cytokines in OVA-immunized BALB/c mice. *Eur J Nutr*. 2007; 46: 257-63.
27. Jenkins LW, Povlishock JT, Lewelt W, Miller JD, Becker DP. The role of postischemic recirculation in the development of ischemic neuronal injury following complete cerebral ischemia. *Acta Neuropathol*. 1981; 55: 205-20.
28. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. *Pharmacol Biochem Behav*. 2006; 85: 66-75.
29. Yang M, Kim JS, Kim J, Kim SH, Kim JC, Kim J, et al. Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro. *Biochem Pharmacol*. 2011; 82: 72-80.
30. Seigers R, Pourtau L, Schagen SB, van Dam FS, Koolhaas JM, Konsman JP, et al. Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. *Brain Res Bull*. 2010; 81: 472-6.
31. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. *J Neurochem*. 2003; 85: 180-92.
32. Uzar E, Sahin O, Koyuncuoglu HR, Uz E, Bas O, Kilbas S, et al. The activity of adenosine deaminase and the level of nitric oxide in spinal cord of methotrexate administered rats: protective effect of caffeic acid phenethyl ester. *Toxicology*. 2006; 218: 125-33.
33. Uz E, Oktem F, Yilmaz HR, Uzar E, Ozguner F. The activities of purine-catabolizing enzymes and the level of nitric oxide in rat kidneys subjected to methotrexate: protective effect of caffeic acid phenethyl ester. *Mol Cell Biochem*. 2005; 277: 165-70.
34. Celik H, Kosar M. Inhibitory effects of dietary flavonoids on purified hepatic NADH-cytochrome b5 reductase: structure-activity relationships. *Chem Biol Interact*. 2012; 197: 103-9.
35. Hong Y, An Z. Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-kappaB signaling. *Arch Pharm Res*. 2018; 41: 655-663.